University of Michigan

Dana-farber-cancer Institute Inc.

University of Southern California

Benedict R Lucchesi

James Douglas Griffin

Paul J Simpson

Robert F Todd, Iii

Stuart F Schlossman

Raymond E Counsell

Francis S Markland, Jr

Mohit Trikha

Stuart F Scholossman

Contortrostatin is employed as active agent for treatment of thrombotic disease. Preferably, contortrostatin is employed in conjunction with at least one thrombolytic agent. In addition, contortrostatin is useful in compositions and methods for preventing metastases in carcinoma and melanoma patients, treating or preventing osteoporosis and promoting wound healing.

Compositions containing contortrostatin and methods for the use thereof

A method of reducing tissue injury in humans or other animal species using a monoclonal antibody to inhibit specific phagocyte functions. The monoclonal antibody is selected to bind to phagocytic leukocytes for the purpose of inhibiting migration to an inflammatory site in the body and to inhibit the adhesion and spreading of activated leukocytes reaching such an area and then, block release of toxic substances by these cells. The monoclonal antibody is administered in vivo prior or early in the course of an experience leading to an injurious inflammatory response such as can result from restoration of myocardial blood flow interrupted by an acute coronary thrombosis.

Method of reducing tissue damage at an inflammatory site using a

The above captioned compounds exhibit potent and long acting anti-arrhythmic activity while lacking the undesirable side effects, e.g. .beta.-adrenergic receptor blocking activity and local anesthetic activity, characteristic of related prior art compounds.

1-(Trialkylamino)-3-(phenylphenoxy)-2-propanol quarternary salts

1-(N-isopropyl-N,N-dimethylamino)-3-(1-naphthoxy)propan-2-ol quaternary salts are useful cardiovascular agents as evidenced by their potent and long-acting anti-arrhythmic, anti-fibrillatory and myocardial ischemia-inhibitory activity. They, furthermore, lack the undesirable side-effects, e.g. .beta.-adrenergic receptor blocking and local anesthetic activity, characteristic of related prior art compounds.

Method of inhibiting myocardial ischemia in mammals using quaternary

Novel quaternary salts and method

Growing community of inventors

Ann Arbor, MI, United States of America

Benedict R Lucchesi